Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Abarelix poised to enter phase III clinical development

June 18, 1998

Irish research organization discovers MAO inhibitor with cytoprotective effects

June 18, 1998

Oncolym makes progress in phase II

June 18, 1998

P&U identifies potent distamycin derivatives with improved therapeutic indices

June 18, 1998

New dihydrofolate reductase inhibitors with antitumor and antiparasitic activities

June 17, 1998

Yissum discloses peptidomimetic protein farnesyltransferase inhibitors

June 17, 1998

Results from antiangiogenic cancer gene therapy reported

June 16, 1998

Taisho presents the topoisomerase II inhibitor NCA-0424

June 16, 1998

Tricyclic compounds inhibiting abnormal cell growth discovered at Schering-Plough

June 16, 1998

Targeted Genetics' E1A gene therapy downregulates HER-2/neu oncogene in phase I

June 16, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...